![Frontiers | Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma Frontiers | Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma](https://www.frontiersin.org/files/Articles/918499/fonc-12-918499-HTML-r2/image_m/fonc-12-918499-g001.jpg)
Frontiers | Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
Crédit Industriel Et Commercial CIC - Banque, 32 av Longueil, 78600 Maisons Laffitte (France) - Adresse, Horaire
![PDF) Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 PDF) Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02](https://i1.rgstatic.net/publication/319293323_Docetaxel_Cisplatin_and_5-fluorouracil_DCF_chemotherapy_in_the_treatment_of_metastatic_or_unresectable_locally_recurrent_anal_squamous_cell_carcinoma_A_phase_II_study_of_French_interdisciplinary_GERCO/links/59a171c7458515fd1fe37977/largepreview.png)